Kisspeptin-10

Kisspeptin-10 has been given to people, though not many. One study gave it intravenously to healthy men: six in a dose-finding arm with a saline comparison, and four in each of two infusion arms lasting 9 and 22.5 hours. Luteinising hormone rose after every injection, peaking within 45 minutes, and during the longer, higher-rate infusion serum testosterone rose too. Every endpoint was a blood measurement taken over hours.

The molecule is the ten-amino-acid tail shared by every natural kisspeptin, the family of peptides cut from the KISS1 gene product. Kisspeptin-54, the long form, carries most of the repeated-dosing human research, and mouse work shows the two behave differently once injected. A finding about one is not a finding about the other.

Kisspeptin-10 is not an approved drug. FDA placed it in Category 2 of the 503A compounding nominations on 29 September 2023, and WADA prohibits it at all times through the class wording "kisspeptin and its agonist analogues".

The KISS1 gene encodes a 145-amino-acid precursor that is cleaved into kisspeptin-54, -14, -13 and -10, each named for its length. All of them end in the same ten amino acids, and that shared end is kisspeptin-10. It is the shortest form that still activates the kisspeptin receptor, KISS1R, at full strength.

Sharing a receptor does not make the forms equivalent in a body. In mice, kisspeptin-10 cleared from the blood with a half-life of about four minutes against about 32 for kisspeptin-54. Researchers who used the long form for multi-day human studies were working with a different pharmacological object, and their results cannot be relabelled as kisspeptin-10 results.

A Switch Above the Pituitary

Kisspeptin neurons in the hypothalamus regulate the neurons that release gonadotrophin-releasing hormone (GnRH), and through them the pulsing pattern of GnRH output. GnRH then tells the pituitary to secrete luteinising hormone (LH) and follicle-stimulating hormone (FSH). In males, LH drives Leydig cells to make testosterone, while FSH supports sperm production.

Two genetic facts show how central the receptor is. Inactivating variants of the KISS1R gene cause congenital hypogonadotropic hypogonadism, a failure of the reproductive hormone axis. In knockout animals lacking the receptor, kisspeptin-10 produces no LH response at all, even though their GnRH neurons and pituitary still work.

What That Position Implies

Because kisspeptin acts several steps upstream of testosterone, its output depends on everything below it. In the 2011 study, the highest bolus tested produced a smaller LH response than the next dose down, and the authors pointed to rapid receptor desensitisation as one plausible explanation. Women showed no gonadotrophin rise to kisspeptin-10 in the follicular phase of the cycle but did respond in the preovulatory phase. The same molecule gives different answers depending on the state of the axis it is pushing.

The libido claims come from the wrong peptide. The 2025 review notes that the human brain-imaging and sexual-behaviour studies of kisspeptin, in men and in premenopausal women, all used kisspeptin-54 rather than kisspeptin-10. The authors suggest the long form's ability to cross the blood-brain barrier may matter for that effect, which is exactly the property the mouse work found weaker in the short form.

An LH rise is being sold as a testosterone protocol. Testosterone moved only during a continuous intravenous infusion lasting most of a day, in four men, measured against their own baseline. Single injections raised LH without a significant testosterone change. Nothing in the record follows anyone for longer than a day.

Short-term stimulation is being read as long-term stimulation. Continuous kisspeptin exposure has caused tachyphylaxis, a loss of response, in male monkeys and in women with hypothalamic amenorrhoea, and adult female rats stopped responding after two days of kisspeptin-10 infusion. The 22.5 hours of human infusion showed no fading, but that window says nothing about weeks.

Kisspeptin-54 safety data is quoted as if it covered kisspeptin-10. The only repeated-dosing study among these sources gave the long form to women, not the short form to men.

For kisspeptin-10 itself, safety information is thin. In the 2011 bolus study, blood pressure, heart rate, oxygen saturation, liver and kidney function, haemoglobin and electrolytes stayed stable and no adverse events were reported. That covers a handful of healthy men under supervision for hours at a time, and nothing beyond.

The repeated-dosing evidence belongs to kisspeptin-54. In a single-blinded, one-way crossover study, five healthy women had a saline month and then a month with a week of twice-daily kisspeptin-54 injections. Menstrual cycles continued in all five, and the pituitary still responded to kisspeptin-54 and GnRH afterwards. The cycle shortened on average from 28.6 to 26.8 days, peak LH came earlier (day 13.0 against 15.2), and the progesterone rise came earlier (day 15.8 against 18.0). A corpus luteum, a sign of recent ovulation, was seen in all five after kisspeptin-54 and in three of five after saline.

FDA's Category 2 listing records the agency's concerns: potential immunogenicity by certain routes, complexities in peptide-related impurities and characterisation of the active ingredient, and an absence of safety information for the proposed routes.

The evidence supports a narrow statement: in healthy men, intravenous kisspeptin-10 raises LH within the hour, and a continuous infusion for most of a day also raised testosterone and LH pulse frequency. Those are real human results, measured carefully, in about fourteen men.

They do not show a durable change in testosterone, and they do not touch strength, recovery, libido or fertility. The peptide's half-life is measured in minutes, its response depends on the state of the axis, and continuous kisspeptin exposure has caused loss of response in other settings. What exists is a well-characterised research tool for probing the hypothalamus, with no outcome trial behind it.

Not kisspeptin-54. The two share a receptor and a ten-amino-acid ending, but in mice the long form lasted about eight times longer in the blood, sustained LH release that the short form could not, and activated GnRH neurons behind the blood-brain barrier that the short form did not.

Not a proven testosterone booster. Testosterone rose in four healthy men during a day-long intravenous infusion and did not change significantly after single injections.

Not available as an approved or routinely compounded medicine. FDA has not approved it. Kisspeptin-10 was placed in Category 2 of the 503A nominations on 29 September 2023, and is one of only six substances in that category today. Category 2 means FDA identified significant safety risks while reviewing the nomination, and Category 2 substances do not receive the enforcement policy that applies to Category 1.

Not allowed in tested sport. WADA's S2.2.1 prints "kisspeptin and its agonist analogues" among testosterone-stimulating peptides in males. Kisspeptin-10 is not printed by name but is captured at class level, prohibited at all times, in and out of competition, as a non-specified substance.

I like kisspeptin-10 as a piece of science. It is one of the few compounds in this library where someone actually put the molecule into people and measured what happened, and the 2011 study is a clean piece of endocrinology.

What I will not do is pretend that a few hours of rising LH in fourteen men answers the questions people bring to it. The most common mistake I see is borrowing kisspeptin-54 results, especially the libido and brain work, and attaching them to the short peptide sold online. Add the FDA Category 2 listing and a standing WADA prohibition, and I see no case for using it outside a research protocol.